Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 0.65 |
| ▸ | EWSR1 | Q01844 | 5/20 | 0.65 |
| ▸ | ERG | P11308 | 1/20 | 0.65 |
| ▸ | ETV1 | P50549 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | MMP8 | P22894 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | CBX7 | O95931 | 2/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486249 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253330 | 0.87 | FLI1 (0.71) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL15337315 | 0.85 | FLI1 (0.77) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253318 | 0.85 | FLI1 (0.77) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679860 | 0.85 | FLI1 (0.65) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17669259 | 0.85 | FLI1 (0.65) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL29810798 | 0.85 | FLI1 (0.65) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679859 | 0.85 | FLI1 (0.65) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL19419568 | 0.84 | FLI1 (0.67) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253333 | 0.82 | FLI1 (0.75) | FLI1EWSR1ERGETV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758481-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758481-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9714222-B2 | Methods and compositions for treating Ewings sarcoma family of tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714222-B2 | Methods and compositions for treating Ewings sarcoma family of tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | NIH - DEITR | 2017-06-08 | — | — | US | disclosed |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | NIH - DEITR | 2017-06-08 | — | — | US | disclosed |
| US-9511050-B2 | Methods and compositions for treating cancer | GEORGETOWN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511050-B2 | Methods and compositions for treating cancer | GEORGETOWN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160263086-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GEORGETOWN UNIVERSITY (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263086-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GEORGETOWN UNIVERSITY (US) | 2016-09-15 | — | — | US | disclosed |
| US-9045415-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045415-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150051260-A1 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS | GEORGETOWN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051260-A1 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS | GEORGETOWN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013155341-A1 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS | GEORGETOWN UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| WO-2008083326-A2 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
| US-20150051260-A1 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS | EWSR1, FLI1, CDC73 | FLI1 2/4885EWSR1 1/4885ERG 81/4885 |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MGMT, TP53, KRAS | FLI1 527/4885EWSR1 17/4885ERG 530/4885 |
| US-20160263086-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MGMT, TP53, KRAS | FLI1 527/4885EWSR1 17/4885ERG 530/4885 |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.